Nutrient intake and body composition variables in Prader-Willi syndrome--effect of growth hormone supplementation and genetic subtype.

What Was Tested

This controlled clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

In patients with Prader-Willi syndrome (PWS), limited information exists on the effects of growth hormone (GH) therapy, gender and genetic subtype on nutrient intake and body composition.

Who Took Part

According to the abstract, 37 individuals were involved.

PubMed indexes the participants as young children, children, teenagers and adults, both men and women.

How the Study Was Run

The researchers set it up as a single-blind study.

In this single-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study one party knew the assignments and the other did not.

In 37 individuals with PWS (20/17 M/F; 21/16 GH+/GH-), dietary intake and body composition (BMI, DEXA) were assessed.

What Was Measured

Topics PubMed links to this paper include Body Composition, Eating, Human Growth Hormone, Inheritance Patterns and Prader-Willi Syndrome.

What This Means in Plain Language

The paper is a single-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 37 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.